Pompano Beach, FL, March 09, 2018 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (OTC: BSEM) (“BioStem” or the “Company”), a global life sciences corporation, providing innovative technologies with a concentration in Pharmaceuticals and Regenerative Medicine, has entered into an agreement with Barbara Krutchkoff, PhD. to provide advisory services to the Company for purposes of proliferating research participation and collaboration in the field of Regenerative Medicine.
As the BSEM lead on scientific affairs, Dr. Krutchkoff will develop and implement initiatives that promote clinical, translational, and basic regenerative medicine research, with the ultimate goal of advancing both science and evidence-based patient care throughout the industry. Among other roles, Dr. Krutchkoff will serve as BSEM’s primary scientific liaison to internal and external partners involved in performing and promoting biomedical research, including the BSEM Scientific Board; federal agencies; other medical societies; coalitions; the biopharmaceutical industry; and policymakers.
Dr. Barbara Krutchkoff, PhD., is a leading consultant for physicians and biomedical start-up companies in regenerative and cellular medicine. She is Executive Director of the Institute of Regenerative and Cellular Medicine (the “IRCM”), and Co-Chair of the IRCM IRB, which provides support for translational research and validation of regenerative therapies. She has spent more than 25 years helping university and industry leaders to bring regenerative medicine safely to patients. Her educational credentials include Physics and Computer Science at the University of Florida, graduate level biomedical engineering at Virginia Tech, a PhD in behavioral psychology, a Doctorate in Integrative Medicine, and Stem Cell Fellowships at UCLA and A4M. She is a board-certified Diplomat and a Fellow of the American Board of Regenerative Medicine. She is also an adjunct professor at the Universite Paris Descartes, and Chair of the IRCM/Regenerative Outcomes committee for the NIH (National Institutes of Health) Orthopedic Registry.
BSEM’s CEO, Henry Van Vurst, said, “BioStem Technologies is excited to have such a diverse and dynamic professional representing and guiding the Company into the global development of Regenerative Medicine. It’s truly an honor to add Dr. Krutchkoff to our team and I appreciate the passion she demonstrates in all her work.”
About BioStem Technologies, Inc. (OTC PINK: BSEM): BioStem Technologies, Inc. is a global life sciences corporation, providing innovative technologies with a concentration in Pharmaceuticals and Regenerative Medicine. The Company’s mission is to discover, develop and produce the most effective Pharmaceutical and Regenerative Medicine products in the world. The Company is comprised of a diverse group of scientists, physicians, and entrepreneurs who collaborate to create innovative products. These technologies improve the Quality of Life for our patients and, as a result, drive shareholder value.
Forward-Looking Statements: Except for statements of historical fact, the matters discussed in this press release are forward looking and made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "future," "plan" or "planned," "expects," believe" or "projected." These forward-looking statements reflect numerous assumptions and involve a variety of risks and uncertainties, many of which are beyond the company's control that may cause actual results to differ materially from stated expectations. These risk factors include, among others, limited operating history, difficulty in developing, exploiting and protecting proprietary technologies, intense competition and additional risk factors, as discussed in reports filed by the Company with OTC Markets.